CASI Pharmaceuticals is a biotechnology business based in the US. CASI Pharmaceuticals shares (CASI) are listed on the NASDAQ and all prices are listed in US Dollars. CASI Pharmaceuticals employs 176 staff and has a trailing 12-month revenue of around $23.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $6.50 |
|---|---|
| 52-week range | $1.90 - $8.48 |
| 50-day moving average | $6.17 |
| 200-day moving average | $5.01 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.03 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.5 from 2024-09-06
| 1 week (2024-08-30) | -1.37% |
|---|---|
| 1 month (2024-08-07) | 3.83% |
| 3 months (2024-06-07) | 87.32% |
| 6 months (2024-03-07) | 15.15% |
| 1 year (2023-09-07) | 203.74% |
|---|---|
| 2 years (2022-09-07) | 58.15% |
| 3 years (2021-09-07) | 286.90% |
| 5 years (2019-09-06) | 84.14% |
| Revenue TTM | $23.1 million |
|---|---|
| Gross profit TTM | $17.6 million |
| Return on assets TTM | -26.6% |
| Return on equity TTM | -85.43% |
| Profit margin | -117.68% |
| Book value | $0.67 |
| Market Capitalization | $101.9 million |
TTM: trailing 12 months
We're not expecting CASI Pharmaceuticals to pay a dividend over the next 12 months.
CASI Pharmaceuticals's shares were split on a 1:10 basis on 1 June 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CASI Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for CASI Pharmaceuticals shares which in turn could have impacted CASI Pharmaceuticals's share price.
Over the last 12 months, CASI Pharmaceuticals's shares have ranged in value from as little as $1.9 up to $8.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CASI Pharmaceuticals's is 0.647. This would suggest that CASI Pharmaceuticals's shares are less volatile than average (for this exchange).
CASI Pharmaceuticals, Inc. , a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd. ; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc. ; and Acrotech Biopharma L.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.